Cardiac Safety of Osimertinib: A Review of Data

Osimertinib is a third-generation, CNS-active, irreversible, oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that potently and selectively inhibits both EGFR-TKI-sensitizing and T790M resistance mutations. We assess the cardiac failure risk in patients receiving osimertini...

Descripción completa

Detalles Bibliográficos
Autores principales: Ewer, Michael S., Tekumalla, Sri Harsha, Walding, Andrew, Atuah, Kwame N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078322/
https://www.ncbi.nlm.nih.gov/pubmed/33356419
http://dx.doi.org/10.1200/JCO.20.01171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078322/
https://www.ncbi.nlm.nih.gov/pubmed/33356419
http://dx.doi.org/10.1200/JCO.20.01171

Ejemplares similares